Centurylink Investment Management Company Has Decreased By $451,866 Its Goldman Sachs Group (GS) Holding; Immunogen Has 1.38 Sentiment

ImmunoGen, Inc. (NASDAQ:IMGN) Logo

Centurylink Investment Management Company decreased Goldman Sachs Group Inc (GS) stake by 15.78% reported in 2017Q4 SEC filing. Centurylink Investment Management Company sold 1,779 shares as Goldman Sachs Group Inc (GS)’s stock declined 4.52%. The Centurylink Investment Management Company holds 9,495 shares with $2.42 million value, down from 11,274 last quarter. Goldman Sachs Group Inc now has $94.75B valuation. The stock decreased 2.28% or $5.84 during the last trading session, reaching $249.97. About 3.62M shares traded or 1.91% up from the average. The Goldman Sachs Group, Inc. (NYSE:GS) has risen 9.66% since April 9, 2017 and is uptrending. It has underperformed by 1.89% the S&P500.

Immunogen Inc (IMGN) investors sentiment increased to 1.38 in 2017 Q4. It’s up 0.22, from 1.16 in 2017Q3. The ratio is positive, as 90 hedge funds increased and started new positions, while 65 reduced and sold their holdings in Immunogen Inc. The hedge funds in our database reported: 101.53 million shares, up from 87.70 million shares in 2017Q3. Also, the number of hedge funds holding Immunogen Inc in top ten positions was flat from 1 to 1 for the same number . Sold All: 26 Reduced: 39 Increased: 53 New Position: 37.

The stock decreased 3.20% or $0.33 during the last trading session, reaching $9.99. About 2.33M shares traded. ImmunoGen, Inc. (IMGN) has risen 195.97% since April 9, 2017 and is uptrending. It has outperformed by 184.42% the S&P500.

ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company has market cap of $1.33 billion. The firm develops its products using its antibody-drug conjugate technology. It currently has negative earnings. The companyÂ’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML.

Redmile Group Llc holds 3.05% of its portfolio in ImmunoGen, Inc. for 10.91 million shares. Fernwood Investment Management Llc owns 224,500 shares or 0.77% of their US portfolio. Moreover, Endurant Capital Management Lp has 0.41% invested in the company for 210,800 shares. The Israel-based Sphera Funds Management Ltd. has invested 0.38% in the stock. Twin Focus Capital Partners Llc, a Massachusetts-based fund reported 113,216 shares.

Since January 1, 0001, it had 0 insider buys, and 12 insider sales for $3.27 million activity.

Investors sentiment increased to 0.99 in Q4 2017. Its up 0.24, from 0.75 in 2017Q3. It increased, as 60 investors sold GS shares while 371 reduced holdings. 106 funds opened positions while 322 raised stakes. 268.85 million shares or 1.06% less from 271.74 million shares in 2017Q3 were reported. Old Second Comml Bank Of Aurora invested in 0.02% or 151 shares. Wharton Business Gp Ltd Limited Liability Company owns 22,502 shares for 0.59% of their portfolio. Parsec Mngmt Incorporated has invested 0.04% of its portfolio in The Goldman Sachs Group, Inc. (NYSE:GS). 1,000 were reported by West Chester Cap Advisors. Anchor Advisors Ltd Llc, Massachusetts-based fund reported 3,742 shares. Marco Inv Mgmt Ltd Com holds 2.64% in The Goldman Sachs Group, Inc. (NYSE:GS) or 67,806 shares. Moors Cabot stated it has 0.06% of its portfolio in The Goldman Sachs Group, Inc. (NYSE:GS). Gabelli Funds Lc holds 0.05% or 34,600 shares in its portfolio. Matthew 25 Corp reported 12.42% of its portfolio in The Goldman Sachs Group, Inc. (NYSE:GS). Td Asset Management Inc invested 0.15% in The Goldman Sachs Group, Inc. (NYSE:GS). New York-based Arrow Corporation has invested 1.03% in The Goldman Sachs Group, Inc. (NYSE:GS). Waddell & Reed Fin Inc holds 516,256 shares. Segment Wealth Management holds 19,279 shares or 1.19% of its portfolio. Swift Run Cap Mngmt Limited Liability Com reported 5.08% stake. Avalon Advsr Lc has invested 0.02% in The Goldman Sachs Group, Inc. (NYSE:GS).

Since October 18, 2017, it had 0 buys, and 10 sales for $31.19 million activity. CHAVEZ R. MARTIN had sold 11,829 shares worth $3.18M on Wednesday, January 31. The insider SCHWARTZ HARVEY M sold $6.13 million. Another trade for 17,500 shares valued at $4.40 million was sold by VINIAR DAVID A. ROGERS JOHN F.W. also sold $1.17M worth of The Goldman Sachs Group, Inc. (NYSE:GS) shares. SALAME PABLO J had sold 10,000 shares worth $2.70M. SOLOMON DAVID M had sold 21,252 shares worth $5.77M on Monday, January 29. LEE BRIAN J also sold $1.78 million worth of The Goldman Sachs Group, Inc. (NYSE:GS) shares.

Among 30 analysts covering Goldman Sachs Group Inc. (NYSE:GS), 13 have Buy rating, 1 Sell and 16 Hold. Therefore 43% are positive. Goldman Sachs Group Inc. has $330.0 highest and $140 lowest target. $249.44’s average target is -0.21% below currents $249.97 stock price. Goldman Sachs Group Inc. had 100 analyst reports since July 21, 2015 according to SRatingsIntel. The stock has “Buy” rating by UBS on Friday, January 6. The firm has “Hold” rating given on Tuesday, December 12 by Keefe Bruyette & Woods. The stock of The Goldman Sachs Group, Inc. (NYSE:GS) has “Overweight” rating given on Thursday, March 15 by Morgan Stanley. The stock has “Market Perform” rating by Wood on Wednesday, July 19. The firm earned “Overweight” rating on Tuesday, February 16 by JP Morgan. As per Thursday, January 18, the company rating was maintained by Barclays Capital. BMO Capital Markets maintained The Goldman Sachs Group, Inc. (NYSE:GS) rating on Friday, October 6. BMO Capital Markets has “Hold” rating and $202.0 target. The firm has “Sell” rating by Berenberg given on Friday, February 24. Deutsche Bank maintained the shares of GS in report on Wednesday, August 12 with “Hold” rating. Rafferty maintained The Goldman Sachs Group, Inc. (NYSE:GS) on Thursday, November 10 with “Buy” rating.

The Goldman Sachs Group, Inc. (NYSE:GS) Institutional Positions Chart